Name : Mrs.

MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107542 / 10313619 Sample Receive Date : 10/Aug/2024 05:33PM
Referred By : SELF Report Status : Final Report
Sample Type : Whole Blood-EDTA Report Date : 10/Aug/2024 06:30PM

HAEMATOLOGY
All Day Health Package Lite - Non-Fasting
Test Name Result Unit Bio. Ref. Interval Method

Complete Blood Count

Hemoglobin 13.1 g/dL 12.0 - 15.0 Cyanide Free SLS
RBC 4.84 10^6/cu.mm 3.8-4.8 Impedance
HCT 40.4 % 36-46 Calculated
MCV 83.5 fL 83 - 101 RBC pulse measurement
MCH 27.1 pg 27 - 32 Calculated
MCHC 32.5 g/dL 31.5 - 34.5 Calculated
RDW-CV 14.0 % 11.6-14 Calculated
Total Leucocyte Count 5.74 10^3/µL 4 - 10 Impedance
Differential Leucocyte Count
Neutrophils 55.8 % 40-80 DHSS/Microscopy
Lymphocytes 31.5 % 20-40 DHSS/Microscopy
Monocytes 8.1 % 2-10 DHSS/Microscopy
Eosinophils 4 % 1-6 DHSS/Microscopy
Basophils 0.6 % 0-2 DHSS/Microscopy
Absolute Leucocyte Count
Absolute Neutrophil Count 3.2 10^3/µL 2-7 Calculated
Absolute Lymphocyte Count 1.81 10^3/µL 1-3 Calculated
Absolute Monocyte Count 0.46 10^3/µL 0.2-1 Calculated
Absolute Eosinophil Count 0.23 10^3/µI 0.02-0.5 Calculated
Absolute Basophil Count 0.03 10^3/µL 0.02-0.1 Calculated
Platelet Count 150 10^3/µL 150-410 Impedance /Microscopy
MPV 12 fL 6.5 - 12 Calculated
PDW 24.2 fL 9-17 Calculated

Comment:
As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are
additionally being reported as absolute numbers of each cell in per unit volume of blood.
DHSS : Double Hydrodynamic Sequential System

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 1 of 12
Name : Mrs.MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107542 / 10313619 Sample Receive Date : 10/Aug/2024 05:33PM
Referred By : SELF Report Status : Final Report
Sample Type : WHOLE BLOOD-EDTA Report Date : 10/Aug/2024 07:40PM

HAEMATOLOGY
All Day Health Package Lite - Non-Fasting
Test Name Result Unit Bio. Ref. Interval Method

Glycosylated Hemoglobin (HbA1c) 5.0 % 4 - 5.6 HPLC (NGSP certified)

Estimated average glucose (eAG) 96.80 mg/dL Calculated

Comment:
Interpretation: HbA1c%

≤5.6 Normal
5.7-6.4 At Risk For Diabetes
≥6.5 Diabetes

Adapted from American Diabetes Association.

Comments:
A 3 to 6 monthly monitoring is recommended in diabetics. People with diabetes should get the test done more often if their blood
sugar stays too high or if their healthcare provider makes any change in the treatment plan. HbA1c concentration represent the
integrated values for blood glucose over the preceding 8-12 weeks and is not affected by daily glucose fluctuation, exercise &
recent food intake.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions,
known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.

Factors that interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified
derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements.

Factors that affect interpretation of HbA1c Measurement: Any condition that shortens erythrocyte survival or decrease mean
erythrocyte age (e. g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test
results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c.

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the
HbA1c result does not correlate with the patient's blood glucose levels.

• HPLC - High performance liquid chromatography

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 2 of 12
 Name : Mrs.MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107537 / 10313619 Sample Receive Date : 10/Aug/2024 05:16PM
Referred By : SELF Report Status : Final Report
Sample Type : Serum Report Date : 10/Aug/2024 08:22PM

BIOCHEMISTRY
All Day Health Package Lite - Non-Fasting
Test Name Result Unit Bio. Ref. Interval Method

LIVER FUNCTION TEST

Liver Function Test
Bilirubin-Total 0.40 mg/dL 0.3 – 1.2 Vanadate oxidation
Bilirubin-Direct 0.13 mg/dL 0.0-0.3 Vanadate oxidation
Bilirubin-Indirect 0.27 mg/dL 0.2-0.8 Calculated
Protein, Total 7.40 g/dL 5.7–8.2 Biuret
Albumin 4.20 g/dL 3.2-4.8 BCG Dye Binding
Globulin 3.2 g/dl 2.3 - 4.1 Calculated
A/G Ratio 1.31 Ratio 0.8 - 1.9 Calculated
Aspartate Transaminase (SGOT) 18 U/L <34 U/L Modified IFCC
Alanine Transaminase (SGPT) 8 U/L 10-49 Modified IFCC
SGOT/SGPT 2.25 Ratio Calculated
Alkaline Phosphatase 46 U/L 46-115 IFCC Standardization
Gamma Glutamyltransferase (GGT) 12 U/L <38 Modified IFCC

Comment:

Raised ALT and AST indicate hepatocellular damage (e.g. viral or drugs etc). ALT is more liver-specific while AST is also
found in heart, skeletal muscle, and kidney. Mild elevation (less than twice normal) often resolves on its own. Fatty liver
disease (especially with metabolic syndrome) is a common cause in asymptomatic cases. Certain drugs (paracetamol,
statins), herbal supplements, energy drinks, and antibiotics may also affect liver function.
SGOT/SGPT Ratio: Typically <1 in healthy individuals (vary between 0.7-1.4; higher in women than men). High SGPT (ratio
<1) seen in acute or chronic hepatitis, autoimmune disorders, medications, toxins while ratio >1 indicates alcoholic
hepatitis, cirrhosis, metastasis or non-hepatic issues (hemolytic diseases, CVS disorders).
Elevated Alkaline Phosphatase and GGT: Suggest cholestatic diseases (e.g. bile duct obstruction, primary biliary
cirrhosis etc.) and can also be due to bone disease, pregnancy, chronic renal failure, malignancy, and congestive heart
failure.
High Bilirubin: Indicates jaundice due to increased RBC breakdown, liver damage (e.g., infections, toxins), or cholestasis
(e.g., gallstones, tumors).
High Protein Levels: Seen in dehydration (e.g., severe vomiting, diarrhea) or increased production (e.g., inflammation,
hematopoietic neoplasms). Low protein and albumin: Result from impaired synthesis (liver disease), decreased intake,

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 3 of 12
Name : Mrs.MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107537 / 10313619 Sample Receive Date : 10/Aug/2024 05:16PM
Referred By : SELF Report Status : Final Report
Sample Type : Serum Report Date : 10/Aug/2024 08:22PM

BIOCHEMISTRY
All Day Health Package Lite - Non-Fasting
Test Name Result Unit Bio. Ref. Interval Method
tissue damage, malabsorption, or increased renal excretion.

Kidney Function Test.

Blood Urea Nitrogen 12 mg/dL 9.0-23 Urease with GLDH
Urea 25.68 mg/dL 19.26-49.22 Calculated
Creatinine 0.87 mg/dL 0.55-1.02 Alkaline picrate-kinetic
Uric Acid 4.4 mg/dL 2.7-6.1 Uricase/Peroxidase
Sodium 140 mEq/L 136-145 Indirect IMT
Potassium 4.49 mEq/L 3.5-5.1 Indirect IMT
Chloride 106.0 mEq/L 98-107 Indirect IMT
BUN/Creatinine Ratio 13.8 Ratio 12:1 - 20:1 Calculated

Comment:
BUN is directly related to protein intake and nitrogen metabolism and inversely related to the rate of excretion of urea.Blood
urea nitrogen (BUN) levels reflect the balance between the production and excretion of urea. Increased levels are seen in renal
failure (acute or chronic), urinary tract obstruction, dehydration, shock, burns, CHF, GI bleeding, nephrotoxic drugs. Decreased
levels are seen in hepatic failure, nephrotic syndrome, cachexia (low-protein and high-carbohydrate diets).
Urea is a non-proteinous nitrogen compound formed in the liver from ammonia as an end product of protein metabolism. Urea
diffuses freely into extracellular and intracellular fluid and is ultimately excreted by the kidneys. Increased levels are found in
acute renal failure, chronic glomerulonephritis, congestive heart failure, decreased renal perfusion, diabetes, excessive protein
ingestion, gastrointestinal (GI) bleeding, hyperalimentation, hypovolemia, ketoacidosis, muscle wasting from starvation,
neoplasms, pyelonephritis, shock, urinary tract obstruction, nephrotoxic drugs. Decreased levels are seen in inadequate dietary
protein, low-protein/high-carbohydrate diet, malabsorption syndromes, pregnancy, severe liver disease, certain drugs.
Creatinine is catabolic product of creatinine phosphate, which is excreted by filtration through the glomerulus and by tubular
secretion. Creatinine clearance is an acceptable clinical measure of glomerular filtration rate (GFR). Increased levels are seen in
acute/chronic renal failure, urinary tract obstruction, hypothyroidism, nephrotoxic drugs, shock, dehydration, congestive heart
failure, diabetes. Decreased levels are found in muscular dystrophy.
BUN/Creatinine ratio (normally 12:1–20:1) is decreased in acute tubular necrosis, advanced liver disease, low protein intake,
and following hemodialysis. BUN/Creatinine ratio is increased in dehydration, GI bleeding, and increased catabolism.
Uric acid levels show diurnal variation. The level is usually higher in the morning and lower in the evening. Increased levels are
seen in starvation, strenuous exercise, malnutrition, or lead poisoning, gout, renal disorders, increased breakdown of body cells
in some cancers (including leukemia, lymphoma, and multiple myeloma) or cancer treatments, hemolytic anemia, sickle cell
anemia, or heart failure, pre-eclampsia, liver disease (cirrhosis), obesity, psoriasis, hypothyroidism, low blood levels of
parathyroid hormone (PTH), certain drugs, foods that are very high in purines - such as organ meats, red meats, some seafood
and beer. Decreased levels are seen in liver disease, Wilson's disease, Syndrome of inappropriate antidiuretic hormone (SIADH),
certain drugs.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 4 of 12
 Name : Mrs.MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107537 / 10313619 Sample Receive Date : 10/Aug/2024 05:16PM
Referred By : SELF Report Status : Final Report
Sample Type : Serum Report Date : 10/Aug/2024 08:22PM

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

Iron Studies, Basic

Iron Serum 90 µg/dL 50-170 Ferrozine
Unsaturated Iron Binding Capacity 221 µg/dL 111-343 Ferene
Total Iron Binding Capacity ( TIBC) 310.8 µg/dL 240 - 540 Calculated
Transferrin Saturation 28.96 % 16-50 Calculated

Comment:

Iron is an essential trace mineral element which forms an important component of hemoglobin, metallocompounds and Vitamin
A. Deficiency of iron is seen in iron deficiency and anaemia of chronic disorders.
Increased iron concentration are seen in hemolytic anaemias, hemochromatosis and acute liver disease. Serum Iron alone is
unreliable due to considerable physiologic diurnal variation in the results with highest values in the morning and lowest values in
the evening as well as variation in response to iron therapy .

Total Iron Binding capacity (TIBC) is a direct measure of the protein Transferrin which transports iron from the gut to storage
sites in the bone marrow. Increased levels of TIBC suggest that total iron body stores are low, increased concentration may be
the sign of Iron deficiency anaemia, polycythemia vera ,and may occur during the third trimester of pregnancy. Decreased levels
may be seen in hemolytic anaemia, hemochromatosis, chronic liver disease, hypoproteinemia ,malnutrition.

Unsaturated Iron Binding Capacity (UIBC) is increased in low iron state and decreased in high iron concentration such as
hemochromatosis. In case of anaemia of chronic disease the patient may be anaemic but has adequate iron reserve and a low
uIBC.

Transferrin Saturation occurs in Idiopathic hemochromatosis and Transfusional hemosiderosis where no unsaturated iron
binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of Transferrin.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 5 of 12
Name : Mrs.MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107538 / 10313619 Sample Receive Date : 10/Aug/2024 05:49PM
Referred By : SELF Report Status : Final Report
Sample Type : Fluoride Plasma R Report Date : 10/Aug/2024 08:22PM

BIOCHEMISTRY
All Day Health Package Lite - Non-Fasting
Test Name Result Unit Bio. Ref. Interval Method

Glucose- Random 90 mg/dl Normal - 70 - 140, Hexokinase

Prediabetes - 140 - 199,
Diabetes - >=200 +
symptoms

Comment:

Random glucose in plasma measures the glucose levels regardless of the last meal intake.

Ref: American Diabetes Association.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 6 of 12
 Name : Mrs.MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107537 / 10313619 Sample Receive Date : 10/Aug/2024 05:16PM
Referred By : SELF Report Status : Final Report
Sample Type : Serum Report Date : 10/Aug/2024 08:22PM

BIOCHEMISTRY
All Day Health Package Lite - Non-Fasting
Test Name Result Unit Bio. Ref. Interval Method

Lipid profile (Non-fasting)

Cholesterol - Total 166 mg/dL Low (desirable): < 200 Enzymatic
mg/dL
Moderate (borderline)
200–239 mg/dL
High: >/= 240 mg/dL
Triglycerides 145 mg/dL Normal: < 150, GPO, Trinder without
Borderline: 150 - 199, serum blank
High:200 - 499, Very
High >=500
Cholesterol - HDL 37 mg/dL Undesirable/high risk Cholesterol Esterase
<=40mg/dL
Desirable/low
risk>=60mg/dl
Cholesterol - LDL 100 mg/dL Desirable: <100 Calculated
Above desirable: 100 -
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 29 mg/dl <30 Calculated
Cholesterol : HDL Cholesterol 4.5 Ratio Desirable : 3.0-4.0 Calculated
High risk : >4
LDL : HDL Cholesterol 2.69 Ratio Desirable : 2.0-2.5 Calculated
High risk : >3.0
Non HDL Cholesterol 129 mg/dl Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 7 of 12
Name : Mrs.MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107537 / 10313619 Sample Receive Date : 10/Aug/2024 05:16PM
Referred By : SELF Report Status : Final Report
Sample Type : Serum Report Date : 10/Aug/2024 08:22PM

BIOCHEMISTRY
All Day Health Package Lite - Non-Fasting
Test Name Result Unit Bio. Ref. Interval Method
Very High: >= 220

Comment:

Total cholesterol is the total amount of cholesterol in blood comprising of HDL, LDL-C, and VLDL.
LDL Cholesterol (LDL-C) or “bad”cholesterol contributes most significantly to atherosclerosis leading to heart disease or
stroke and is the primary target for reducing risk for cardiovascular disease (CVD).
High-density lipoprotein (HDL-C) or “good” cholesterol can lower risk of heart disease and stroke.
Triglyceride (TG) level also plays a major role in CVD and need treatment. Indians are more prone to atherogenic
dyslipidemia, a condition with high TG, low HDL-C and high LDL-C; seen in diabetes, metabolic syndrome and insulin
resistance.
Non-HDL-Cholesterol (Non-HDLC) measures all plaque forming lipoproteins (e.g. remnants, LDL-C, VLDL, Lp(a), Apo-B).

The Lipid Association of India (LAI) recommends

Screening of all adults above the age of 20 years for Atherosclerotic Cardiovascular Disease (ASCVD) risk factors, esp. lipid
profile. Risk factors for CVD include: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age
(<55 yrs in males, <65 yrs in female), Smoking/tobacco use, High blood pressure, Low HDL (males <40 mg/dl and females
<50mg/dl).
LAI recommends LDL-Cholesterol (LDL-C) as the primary target and Non-HDL-Cholesterol (Non-HDLC) as a co-primary
target, for lipid-lowering therapy.
The Lipid Association of India (LAI-2020) recommends that both fasting and non-fasting lipid profiles are important for
managing Indian patients with dyslipidemia. The Non-fasting lipid profile helps to determine post
prandial hypertriglyceridemia, blood sampling is simplified for patients and doctors; better for pateint follow-up.
Non-fasting lipid profile is preferred in primary prevention settings, e.g. mass screening of a community; initial lipid profile
or CVD risk assesment of a patient if he is non-fasting; emergency assessment of a pancreatitis patient or patients
admitted with acute chest pain; in children or elderly; diabetic patients with risk of hypoglycemia.
A subsequent lipid profile (after 10-12 hrs fasting) may be required if:- Non-fasting triglycerides >400 mg/dL; known
hypertriglyceridemia on treatment or recovering from hypertriglyceridaemic pancreatitis; starting medications that cause
severe hypertriglyceridemia; to monitor LDL-C level after starting drug therapy.

Note: Reference Interval as per National Cholesterol Education Program (NCEP) Report

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 8 of 12
Name : Mrs.MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107537 / 10313619 Sample Receive Date : 10/Aug/2024 05:16PM
Referred By : SELF Report Status : Final Report
Sample Type : Serum Report Date : 10/Aug/2024 07:54PM

Immunology
All Day Health Package Lite - Non-Fasting
Test Name Result Unit Bio. Ref. Interval Method

Thyroid Profile
T3, Total 0.76 ng/mL 0.60-1.81 CLIA
T4, Total 6.8 µg/dl 4.5-12.6 CLIA
Thyroid Stimulating Hormone - Ultra 5.860 uIU/ml 0.55-4.78 CLIA
Sensitive

Comment:

Below mentioned are the guidelines for pregnancy related reference ranges for TSH, total T3 & Total T4.

Pregnancy
TSH (μIU/mL) (as per
American Thyroid Total T3 (ng/mL) Total T4(μg/dL)
Association )
1st trimester 0.1-2.5 0.81-1.90 7.33-14.8
2nd trimester 0.2-3.0 1.00-2.60 7.93-16.1
3rd trimester 0.3-3.0 1.00-2.60 6.95-15.7

TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum between 6-10 pm
.
The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
TSH is secreted in a dual fashion: Intermittent pulses constitute 60-70% of total amount, background continuous secretion
is 30-40%.These pulses occur regularly every 1-3 hrs.
Total T3 & T4 concentrations are altered by physiological or pathological changes in thyroxine binding globulin (TBG)
capacity .
The determination of free T3 & free T4 has the advantage of being independent of changes in the concentrations and
binding properties of the binding proteins.
Changes in thyroid status are typically associated with concordant changes in T3, T4 and TSH levels.
Unexpectedly abnormal or discordant thyroid test values may be seen with some rare, but clinically significant conditions
such as central hypothyroidism, TSH-secreting pituitary tumors, thyroid hormone resistance, or the presence of
heterophilic antibodies (HAMA) or thyroid hormone autoantibodies.
For diagnostic purposes, results should be used in conjunction with other data.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 9 of 12
Name : Mrs.MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107537 / 10313619 Sample Receive Date : 10/Aug/2024 05:16PM
Referred By : SELF Report Status : Final Report
Sample Type : Serum Report Date : 10/Aug/2024 07:54PM

Immunology
All Day Health Package Lite - Non-Fasting
Test Name Result Unit Bio. Ref. Interval Method
TSH T3 T4 Interpretation
High Normal Normal Subclinical Hypothyroidism
Low Normal Normal Subclinical Hyperthyroidism
High High High Secondary Hyperthyroidism
Low High/Normal High/Normal Hyperthyroidism
Non thyroidal illness / Secondary
Low Low Low Hypothyroidism

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 10 of 12
 Name : Mrs.MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107537 / 10313619 Sample Receive Date : 10/Aug/2024 05:16PM
Referred By : SELF Report Status : Final Report
Sample Type : Serum Report Date : 10/Aug/2024 07:54PM

Immunology
Test Name Result Unit Bio. Ref. Interval Method

Vitamin D (25-OH)
Vitamin D (25-OH) 9.1 ng/ml Deficiency:< 20, CLIA
Insufficiency:20-29,
Sufficiency:30 - 100,
Toxicity possible:> 100

Comment:

Vitamin D is a fat-soluble steroid prohormone involved in the intestinal absorption of calcium and the regulation of calcium
homeostasis.
Two forms of vitamin D are biologically relevant - vitamin D3 (Cholecalciferol) and vitamin D2 (Ergocalciferol).
Both vitamins D3 and D2 can be absorbed from food but only an estimated 10-20perc. of vitamin D is supplied through
nutritional intake.
Vitamin D is converted to the active hormone 1,25-(OH)2-vitamin D (Calcitriol) through two hydroxylation reactions. The
first hydroxylation converts vitamin D into 25-OH vitamin D and occurs in the liver. The second hydroxylation converts 25-
OH vitamin D into the biologically active 1,25-(OH)2-vitamin D and occurs in the kidneys as well as in many other cells of
the body.
Most cells express the vitamin D receptor and about 3perc. of the human genome is directly or indirectly regulated by the
vitamin D endocrine system.
The major storage form of vitamin D is 25-OH vitamin D and is present in the blood at up to 1,000 fold higher
concentration compared to the active 1,25-(OH)2-vitamin D. 25-OH vitamin D has a half-life of 2-3 weeks vs. 4 hours for
1,25-(OH)2-vitamin D. Therefore, 25-OH vitamin D is the analyte of choice for determination of the vitamin D status.
Risk factors for vitamin D deficiency include low sun exposure, inadequate intake, decreased absorption, abnormal
metabolism, vitamin D resistance and and liver or kidney diseases.
Vitamin D deficiency is a cause of secondary hyperparathyroidism and diseases resulting in impaired bone metabolism (like
rickets, osteomalacia).
Recently, many chronic diseases such as cancer, high blood pressure, osteoporosis and several autoimmune diseases
have been linked to vitamin D deficiency.
The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D

Utility Quantitative determination of 25-hydroxyvitamin D (25-OH vitamin D).

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 11 of 12
 Name : Mrs.MANISHA JOSHI Client Name : RETAIL TATA 1MG - SECTOR 137 NOID
Age/Gender : 33 Y 0 M 0 D /Female Registration Date : 10/Aug/2024 08:18AM
Patient ID : OKH1510689 Collection Date : 10/Aug/2024 07:00AM
Barcode ID/Order ID : D9107537 / 10313619 Sample Receive Date : 10/Aug/2024 05:16PM
Referred By : SELF Report Status : Final Report
Sample Type : Serum Report Date : 10/Aug/2024 07:54PM

Immunology
Test Name Result Unit Bio. Ref. Interval Method
*** End Of Report ***
Conditions of Laboratory Testing & Reporting:
Test results released pertain to the sample, as received. Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should
be clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report
may vary depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal
purposes. Please mail your queries related to test results to Customer Care mall ID [email protected]

Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All
lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes.
Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the
information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be
vetted by a qualified doctor only.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 12 of 12
 Ensuring accuracy IN every single report
Following a 3-step review process:

Advanced systems & Experienced lab experts Each report undergoes

cutting-edge technology analyze and technicians conduct rigorous medical scrutiny & is
results with precision comprehensive reviews signed off by a doctor

Have concerns regarding the report?

Reach out to our care team at [email protected]
or chat with us
CONNECT NOW >

Accurate Testing, Assured Quality: Diagnostics Precision

Stringent quality control Cutting-edge technology Experienced lab staff

Measures meeting Robust healthcare systems 30+ medical professionals
international norms of safety equipped with calibrated & with a collective
guidelines well-maintained machinery experience of 200+ years

Verified test procedures External assessments Trained phlebotomists

Highly standardized test Thorough third-party Ensuring smooth sample
procedures following CLSI* assessment by authorized collection experience &
guidelines experts pre-analytical precision

Claim FREE doctor consultation

Watch how
Consult top doctors from
the comfort of your home
we take care of
your sample
SCHEDULE NOW>

Get Second Opinion Order Medicines EXPLORE NOW >

Explore Financial Need Help?

Book Lab Tests
Support & more 1800-102-1618

*Clinical & Laboratory Standards Institute T&C Apply